PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.98%
R&D change of 7.98% versus flat Healthcare spending. Walter Schloss would verify adequacy.
58.15%
G&A change of 58.15% versus flat Healthcare overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.40%
Operating expenses growth exceeding 1.5x Healthcare median of 5.04%. Jim Chanos would check for waste.
20.40%
Total costs growth exceeding 1.5x Healthcare median of 5.98%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
2.78%
D&A growth exceeding 1.5x Healthcare median of 0.63%. Jim Chanos would check for overinvestment.
-20.82%
EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Operating income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
97.30%
Other expenses growth while Healthcare reduces costs. Peter Lynch would examine differences.
-19.78%
Pre-tax income decline while Healthcare median is -0.18%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.78%
Net income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
12.20%
EPS growth exceeding 1.5x Healthcare median of 3.88%. Joel Greenblatt would investigate advantages.
12.20%
Diluted EPS growth exceeding 1.5x Healthcare median of 4.00%. Joel Greenblatt would investigate advantages.
35.62%
Share count reduction below 50% of Healthcare median of 0.28%. Jim Chanos would check for issues.
35.62%
Diluted share reduction below 50% of Healthcare median of 0.27%. Jim Chanos would check for issues.